IL-6 and other biomarkers as predictors of severity in COVID-19

• Published in: Annals of medicine (Helsinki) Vol. 53; no. 1; pp. 410 - 412
• Main Authors: Broman, N., Rantasärkkä, K., Feuth, T., Valtonen, M., Waris, M., Hohenthal, U., Rintala, E., Karlsson, A., Marttila, H., Peltola, V., Vuorinen, T., Oksi, J.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.01.2021; Taylor & Francis Group
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers - blood; COVID-19; COVID-19 - blood; COVID-19 - diagnosis; cytokine release syndrome; cytokine storm; Female; Humans; Infectious Diseases; inflammatory phase; interferon; interleukin; Interleukin-6 - blood; Male; Middle Aged; Severity of Illness Index; tocilizumab; Young Adult; COVID-19; tocilizumab; cytokine storm; inflammatory phase; cytokine release syndrome; interferon; interleukin

Cytokine release syndrome is suggested to be the most important mechanism triggering acute respiratory distress syndrome and end organ damage in COVID-19. The severity of disease may be measured by different biomarkers. We studied markers of inflammation and coagulation as recorded in 29 patients on...